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SUMMARY 
Since the early days of antiretroviral therapy, adherence has emerged a milestone to 
success. The objective of this study was to evaluate the factors militating against 
adherence to antiretroviral therapy among HIV-infected individuals in the resource – 
limited setting of the Niger Delta of Nigeria. A structured interviewer- administered 
questionnaire from consecutively recruited 187 HIV-infected patients on combination 
antiretroviral therapy of two-nucleoside analogue; stavudine and lamivudine and one 
non-nucleoside (nevirapine) was used. Association between the independent variables 
and adherence were analyzed using chi square analysis. This study observed an 
adherence level of 49.2% and identified the following as factors associated with non-
adherence: cost of antiretrovirals, educational status, medication adverse effect, 
occupational factors, and high pill burden of prescribed regimen (p < 0.05). There is an 
urgent need for universal access and sustainability of antiretroviral therapy particularly 
in resource – limited settings. There is need for supervised medication delivery. Efforts 
should be made towards simplifying the therapeutic regimen to reduce the pill burden 
and substitution with treatment combination and strategies that minimize negative 
adverse effects, coupled with the re-intensification of patient’s education and counseling. 
 
[Afr J Health Sci. 2006; 13:13-17] 
 
Introduction 
HIV/AIDS remains the greatest health crisis in the 
world today with an estimated 40 million people 
now living with HIV/AIDS, 95% of them in 
developing countries [1]. With the development 
and widespread use of antiretrovirals in the 
developed world, there has been a transformed 
perception of HIV/AIDS from a fatal incurable 
disease to a manageable chronic illness [2]. This 
treatment causes improvement in immunologic 
status and a reduction in the viral load [3, 4] thus 
reducing the incidence of hospitalization and 
mortality [5, 6]. Treatment effectiveness however 
requires a high level of adherence to medication 
regimen [7].  Missing of even a few doses of 
antiretroviral medication can lead to drug resistant 
strains of HIV [8]. Low adherence has been 
associated with detectable viral load (> 500 viral 
RNA copies/ ml of plasma) [9] and with cross-
resistance to other antiretrovirals of the same class 
[10, 11].   
     Cross-resistance can potentially interfere with 
future therapeutic regimens for HIV-infected 
patients undergoing treatment and for those who 





of HIV. Low adherence can lead to devastating 
public health problems. An adherent patient is 
defined as one who takes > 95% of the prescribed 
doses [12].  However a significant proportion of 
HIV-infected patients do not reach high levels of 
adherence.  In this study we aim to determine the 
level of adherence and evaluate factors responsible 
for non-adherence to antiretroviral therapy among 
HIV-infected Nigerians. 
 
Materials and Methods 
A total of 187 consecutively recruited HIV-infected 
were prescribed antiretroviral drugs from June 
2002 to January 2005. They were made up of 82 
males and 105 females and were aged between 19 
to 68 years (mean age 35.54 + 9.42 years). They 
were recruited into the Federal Government 
subsidized antiretroviral therapy programme and 
the hospital antiretroviral initiative at the 
University of Port Harcourt Teaching Hospital. 
These constituted the subjects of this study. The 
hospital is a large 500-bed teaching hospital in the 
cosmopolitan oil rich city of Port Harcourt in the 
heart of the oil and gas industry of the Niger Delta 
of Nigeria.  Inclusion criteria included age >18 
years, use of antiretroviral therapy for a minimum 
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of 6 months, HIV positivity and willingness to give 
informed consent. The patients had received a fixed 
HAART of stavudine (40mg) lamivudine (150mg) 
and nevirapine (250mg) twice daily for a minimum 
of 6 months. Reasons for non adherence were 
assessed using a structured interviewer-
administered questionnaire which included socio-
demographic data of age, sex as well as 
employment status, current income, highest level of 
education, perception to adverse events associated 
with medication, perception to high pill burden of 
prescribed regimen, perception of cost of 
laboratory test for monitoring treatment outcome 
and reasons for non- adherence to treatment. The 
interviewers were trained social   workers and 
counselors attached to the antiretroviral clinic in 
the hospital. All eligible participants were offered 
pre-interview counseling. The interview was 
carried out in English language except for 20 
participants who could not understand English 
language who had to be interviewed in their local 
languages through the help of an interviewer. 
Inclusion criteria included age > 18 years, HIV 
positivity, minimum of 6 months use of 
antiretroviral use prior to the time of interview and 




Data was entered and analyzed using a statistical 
package (Version 9 SPSS).  Statistical analysis 
included descriptive analysis of mean, standard 
deviation and chi square analysis.  Predictions of 
non-adherence were assessed with multivariate 
logistic regression.  A p-value of < 0.05 was 
considered significant in all statistical analysis. 
 
Results 
One hundred and eighty-seven (187) eligible 
respondents made up of 105 females (56.2%) and 
82 males (43.8%), aged 19 – 68 years (mean age 
35.51 + 9.42) constituted the subjects for this study. 
Monthly income ranged from #500 to #75,000 
(mean income 9,127 + 11,376) Naira. Majority of 
respondents 80 (42.8%) were on monthly income 
less than the national minimum wage of # 7,500 
(about $54). All patients have had more than 6 
months of antiretroviral treatment. Antiretroviral 
therapy consisted of a fixed HAART combination 
therapy of stavudine (40 mg), lamivudine (150 mg) 
and nevirapine (250 mg) orally twice daily. All 
patients used 6 or more pills per day. Patients were 
in two treatment groups; the Federal government of 
Nigeria subsidized initiative 121 (64.7%) under 
which antiretroviral regimen were accessed at a 
subsidized rate of #1000 (about $7) and the 
Hospital initiative 66 (35.3%) where drugs are 
accessed at the rate of #7,000 (about $50). 
Respondent’s marital status included single 85 
(45.3%); married 75 (40.1%) divorced 11 (5.9%) 
and widowed 17 (8.6%). Baseline characteristics of 
subjects are shown in Table 1. Of the 187 
participants on antiretrovirals 92 (49.2%) were 
adherent while 95 (50.8%) were non-adherent. 
Adherence was higher among respondents on the 
Federal government antiretroviral initiative 66 
(55.5%) compared to the Hospital initiative 
(33.3%). Reasons for non-adherence ranged from; 
cost constraints 53 (55.8%) unavailability of drugs 
18 (18.9%), medication side effects 17 (17.9%), 
doctor’s strike 3 (3.2%), pregnancy 1 (1.1%) and 
job related transfers 3 (3.2%)  (X2 = 8.93, p=0.01). 
Medication - associated adverse events included; 
nausea and vomiting 3(17.6%), Steven Johnson’s 
syndrome 9(52.9%), jaundice 2(11.8%) and leg 
swelling 3(17.6%). History of non-adherence to 
therapy was compared based on educational status.  
       Non-adherence was relatively higher among 
less-educated respondents with non-formal 
education 30 (31.6%) and primary education 27 
(21.1%) compared to better educated with 
secondary 20(21.1%) and tertiary education 18 
(18.9%). This difference however was not 
statistically significant (X2 = 2.73, p = 0.32). Non-
adherence was compared based on occupational 
groups. Non-adherence was significantly higher 
among applicants 30 (31.6%) compared to other 
professional groups (X2 =6.11, p = 0.01). Of the 
187 respondents, 23 (12.3%) claimed to have 
shared their medication with their HIV-infected 
spouses 19 (82.6%) and children 4 (17.4%) due to 
cost constraints. Respondent’s perception to pill 
burden of prescribed regimen prescribed indicated 
that 139(74.3%) had a negative perception to a high 
pill burden and would prefer a regimen with a low 
pill burden while 48(25.7%) had a positive 
perception (p = 0.001). The reasons for non-
adherence are shown in Table 2. 
       Unavailability of drugs was the observed 
reason for non-adherence to antiretroviral regimen 
among 18.9% of non-adherent respondents. 
Adverse events associated with medication were 
the cited reason for non-adherence in 17.9% of 
non-adherent respondents. Non-adherence was 
relatively higher among less- educated respondents 
without formal education (31.6%) and primary 
education (28.4%) compared to better-educated 
with secondary (21.1%) and tertiary education 
(18.9%). The level of adherence based on marital 
status, educational status and occupation is shown 
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Age    
Median (range) 35.04 + 8.06 34.21+ 7.64 0.32 
Income    
Median (range) 29,740 + 8.93 7,624 + 5.81 0.001 
Sex    
Males 24 (26.1) 58 (61.1) 0.001 
Females 66 (73.9) 37 (38.9)  
Adherence based on treatment groups    
Hospital initiative 22 (33.3) 44 (66.7) 0.001 
Federal government  66 (55.5)   
 
Table 2: Reasons for non-adherence to therapy 
Reason for non-adherence n % p-value 
Non-availability 18 19.0 0.001 
Cost constraint 53 55.8  
Medication side effects 17 17.9  
Doctors strike 3 3.2  
Pregnancy 1 1.1  
Job-related  3 3.2  
 
Discussion 
Since the early days of antiretroviral therapy, 
adherence has emerged as a milestone to success 
and had remained the most potent predictor of 
effectiveness. We observed a low adherence rate of 
49.2%. Our observed adherence rate is consistent 
with a 49% observed in a previous study [13]. It is 
however lower than that obtained in a similar study 
in which 69% of patients used 95% of prescribed 




antiretrovirals in Nigeria a country with a very low 
per capital income may have been responsible for 
the low adherence rate observed in this study. The 
experience in South Africa a country where 
reduction in the prices of antiretrovirals has greatly 
improved adherence brings to bear the potential 
benefits that prize reduction may have on 
adherence to therapy particularly in resource-poor 
settings in sub Saharan Africa.   
 
Table 3: Adherence to therapy based on marital status, educational status and occupation. 
Variable n (%) n (%) p-value 
Marital status    
Single 47 (51.1) 38 (40.0) 0.004 
Married 35 (38.0) 40 (42.1)  
Divorced 4 (4.3) 7 (7.4)  
Widowed 6 (6.5) 10 (10.5)  
Educational status    
Non formal 21 (22.8) 30 (31.6) 0.005 
Primary 19 (20.7) 27 (28.4)  
Secondary 27 (29.3) 20 (21.1)  
Tertiary 25 (27.2) 18 (18.9)  
Occupational groups    
Business 5 (5.4) 10(10.5) 0.001 
Health care worker 1 (1.1) 1(1.1)  
Clergy 1(1.1) 2(2.1)  
Applicants 19 (20.7) 30(31.6)  
Armed forces 4 (4.3) 4(4.2)  
Artisan 22 (23.9) 14(14.7)  
Civil servant 17 (18.5) 12(12.6)  
Farmer 1 (1.1) 5(5.3)  
House wife 6 (6.5) 6(6.3)  
Students 16 (17.4) 11(11.5)  
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Non-adherence was significantly higher among 
unemployed respondents compared to other groups.  
Also the adherence was significantly higher in 
patients on the highly subsidized Federal 
government initiative compared to the more 
expensive hospital initiative.  Cost constraints were 
the major reason for non-adherence in 55.8% of 
non-adherent patients.  We observed a mean 
monthly income of # 9,127 + 11,376 Naira (about $ 
65).  There is need for reduction in the cost of 
antiretrovirals.  High pricing of antiretrovirals and 
associated low monthly income are major factors 
associated with non-adherence to antiretroviral 
particularly in resource-limited settings [14, 15, 
16].  Cost constraints have remained a limiting 
factor on adherence to antiretroviral agents. 
National government particularly those in sub-
Saharan Africa have prolonged reluctance to 
provide the best possible treatment citing numerous 
concerns ranging from cost to the ability of patients 
to adhere to complex life long treatment.  
      South Africa a country with more than 5 
million citizens living with HIV/AIDS has proved 
the pundits wrong. The prices of antiretrovirals 
having precipitously plummeted by more than 95% 
as a result of government developing the desired 
political will to take the challenge of universal 
access to treatment. This strategic and humanitarian 
obligation has resulted in an increase in adherence 
to a high level of more than 90%.  The World 
Health Organization must remain resolute on their 
initiative to get 3 million people living with 
HIV/AIDS in resource-limited settings, on 
antiretroviral therapy by the end of 2005.  This is 
likely to become a giant step toward achieving the 
goal of universal access particularly in resource – 
limited setting in sub-Saharan Africa where 
paradoxically the greatest disease burden exist but 
with less than 8% having access [1]. 
      Unavailability of drugs was the observed 
reason for non-adherence to antiretroviral therapy 
among (18.9%) of non-adherent respondents.  
Evaluation of most antiretroviral initiative in 
resource-poor setting has shown that the purchase, 
supply and distribution of antiretrovirals are not 
properly coordinated.  In most cases there is no 
adhoc plan and no commodity management plan.  
This has often led to stock out and expired drugs 
thus producing a negative effect on adherence to 
therapy [14]. 
     Adverse events associated with medication were 
the cited reason for non-adherence in (17.9%) of 
non-adherent respondents. Antiretroviral associated 
adverse events can contribute a lot to the 
degeneration of HAART –related quality of life of 
HIV-infected [17].  It is unfortunate that up to 25% 
of HIV-infected patients discontinue their initial 
HAART regimen because of toxic effect of therapy 
[18]. There is need to find treatment combinations 
and strategies that minimize these negative effects.  
Low adherence can result in cross-resistance to 
other antiretrovirals [18]. Cross-resistance can 
potentially interfere with future therapeutic option 
for those being treated and those who subsequently 
become infected with resistance virus. 
        Non-adherence was relatively higher among 
less educated respondents compared to better 
educated (secondary and tertiary).  Speculatively 
better educated people generally have greater 
access to information and are more likely to make 
better-informed decisions.  They generally have 
better jobs and greater access to money to regularly 
procure their drugs and support healthier and 
productive lives.  Low adherence can have a 
devastating effect on the individual and can also 
pose an even greater problem for public health. 
       A significant majority of respondents indicated 
a negative perception to the high pill burden of 
antiretroviral regimen prescribed.  Difficulty in 
taking large number of pills can negatively affect 
adherence to therapy [19].  Efforts should be made 
towards simplifying therapeutic regimen to reduce 
the number of daily doses. Increasing the simplicity 
of antiretrovirals promotes adherence and leads to 
extremely high therapeutic success in both 
developing and developed countries. A significant 
majority of respondents (94.1%) believed that the 
use of mechanical aids like pagers and pills boxes 
could improve adherence to therapy.  Emphasis on 
instruction of patients to take medication is 
fundamental as well as patient’s participation in 
treatment decisions is advocated [20].  It is also 
important to stimulate the patients to implement 
therapeutic regimen into their daily routine. 
        There is an urgent need for universal access 
and sustainability of antiretroviral therapy in 
resources – poor settings particularly in sub 
Saharan Africa. Increasing the simplicity of 
antiretroviral regimens and substitution of regimens 
associated with significant adverse effects could 
potentially improve adherence to therapy. 
Provision of family and social support coupled with 
a re-intensified patient’s education and counseling 
can potentially promote adherence, lead to high 




This study indicates a low level of adherence to 
antiretroviral therapy. There is an urgent need for 
universal access and sustainability of antiretroviral 
therapy particularly in resource – limited settings. 
There is need for supervised medication delivery. 
Efforts should be made towards simplifying the 
therapeutic regimen to reduce the pill burden and 
substitution with treatment combination and 
strategies that minimize negative adverse effects, 
coupled with the re-intensification of patient’s 
education and counseling 
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